Transcatheter aortic valve implantation significantly increased mean left ventricular ejection fraction from 53.9% at baseline to 63.2% at 12 months in patients with severe aortic stenosis.
Cohort (n=104)
No
Does transcatheter aortic valve implantation (TAVI) improve left ventricular ejection fraction in patients with reduced ejection fraction?
Transfemoral TAVI is safe and effectively improves left ventricular ejection fraction in patients with aortic stenosis and reduced ejection fraction.
Absolute Event Rate: 63.2% vs 53.9%
p-value: p=<0.001
BACKGROUND: Aortic stenosis increases with age. According to guidelines, left ventricular systolic dysfunction is an indication for aortic valve replacement, even in asymptomatic patients. There is no clear data on the application of transcatheter aortic valve implantation (TAVI), which is a method showing continuous improvement in recent years, in patients with reduced ejection fraction (REF) having a poor prognosis for surgical aortic valve replacement. We therefore aimed to investigate the effect of TAVI on left ventricular ejection fraction (LVEF) and also its efficacy and safety in patients with REF. METHODS AND RESULTS: The study included 104 patients who underwent transfemoral TAVI in our clinic. The patients were divided into two groups: LVEF ≤ 45% (REF group, n = 28) and LVEF > 45% (preserved ejection fraction PEF group, n = 76). Follow-up measurements were performed at baseline, discharge, 1st, 6th and 12th months. No statistical difference was found between the groups with respect to complications and mortality rates. A statistically significant difference was detected in LVEF after TAVI, either in all patients (53.9 ± 14.6, 57.0 ± 11.4, 59.4 ± 8.4, 60.4 ± 6.8, 63.2 ± 3.9, respectively, at baseline, discharge, 1st, 6th and 12th months, p < 0.001) or in the groups separately. A statistically significant increase in LVEF (p < 0.001) was determined at discharge, 1st, 6th and 12th months, whereas LVEF increased in all follow-ups of the PEF group, however this elevation reached a statistical significance only at the 1st month (p = 0.04). CONCLUSIONS: Our study has shown the positive effect of TAVI on LVEF and its effective and safe applicability in patients with REF.
Ayhan et al. (Tue,) conducted a cohort in Severe aortic stenosis (n=104). Transcatheter aortic valve implantation (TAVI) vs. Baseline was evaluated on Left ventricular ejection fraction (LVEF) at 12 months (p=<0.001). Transcatheter aortic valve implantation significantly increased mean left ventricular ejection fraction from 53.9% at baseline to 63.2% at 12 months in patients with severe aortic stenosis.